GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » XBiotech Inc (NAS:XBIT) » Definitions » Interest Coverage

XBiotech (XBiotech) Interest Coverage : No Debt (1) (As of Mar. 2024)


View and export this data going back to 2015. Start your Free Trial

What is XBiotech Interest Coverage?

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income by its Interest Expense. XBiotech's Operating Income for the three months ended in Mar. 2024 was $-10.85 Mil. XBiotech's Interest Expense for the three months ended in Mar. 2024 was $0.00 Mil. XBiotech has no debt. The higher the ratio, the stronger the company's financial strength is.

Good Sign:

Ben Graham prefers companies' interest coverage to be at least 5. XBiotech Inc has enough cash to cover all of its debt. Its financial situation is stable.

(1) Note: For Interest Coverage, "No debt" indicates no long-term debt. An indication of "No Debt" does not necessarily mean that the company has no long-term debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.

The historical rank and industry rank for XBiotech's Interest Coverage or its related term are showing as below:

XBIT' s Interest Coverage Range Over the Past 10 Years
Min: No Debt   Med: No Debt   Max: No Debt
Current: No Debt


XBIT's Interest Coverage is ranked better than
99.41% of 340 companies
in the Biotechnology industry
Industry Median: 138.73 vs XBIT: No Debt

Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.


XBiotech Interest Coverage Historical Data

The historical data trend for XBiotech's Interest Coverage can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Note: For Interest Coverage, "No debt" indicates no long-term debt. An indication of "No Debt" does not necessarily mean that the company has no long-term debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.

* Premium members only.

XBiotech Interest Coverage Chart

XBiotech Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Interest Coverage
Get a 7-Day Free Trial Premium Member Only Premium Member Only No Debt No Debt No Debt No Debt No Debt

XBiotech Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Interest Coverage Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only No Debt No Debt No Debt No Debt No Debt

Competitive Comparison of XBiotech's Interest Coverage

For the Biotechnology subindustry, XBiotech's Interest Coverage, along with its competitors' market caps and Interest Coverage data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


XBiotech's Interest Coverage Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, XBiotech's Interest Coverage distribution charts can be found below:

* The bar in red indicates where XBiotech's Interest Coverage falls into.



XBiotech Interest Coverage Calculation

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income (EBIT) by its Interest Expense:

If Interest Expense is negative and Operating Income is positive, then

Interest Coverage=-1* Operating Income /Interest Expense

Else if Interest Expense is negative and Operating Income is negative, then

The company did not have earnings to cover the interest expense.

Else if Interest Expense is 0 and Long-Term Debt & Capital Lease Obligation is 0, then

The company had no debt (1).


Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

XBiotech's Interest Coverage for the fiscal year that ended in Dec. 2023 is calculated as

Here, for the fiscal year that ended in Dec. 2023, XBiotech's Interest Expense was $0.00 Mil. Its Operating Income was $-37.51 Mil. And its Long-Term Debt & Capital Lease Obligation was $0.00 Mil.

XBiotech had no debt (1).

XBiotech's Interest Coverage for the quarter that ended in Mar. 2024 is calculated as

Here, for the three months ended in Mar. 2024, XBiotech's Interest Expense was $0.00 Mil. Its Operating Income was $-10.85 Mil. And its Long-Term Debt & Capital Lease Obligation was $0.00 Mil.

XBiotech had no debt (1).

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

The higher the ratio, the stronger the company's Financial Strength is.


XBiotech  (NAS:XBIT) Interest Coverage Explanation

Ben Graham requires that a company has a minimum interest coverage of 5 with the companies he invested. If the interest coverage is less than 2, the company is burdened by debt. Any business slow or recession may drag the company into a situation where it cannot pay the interest on its debt.

Interest Coverage is an important factor when GuruFocus ranks a company's overage Financial Strength .


XBiotech Interest Coverage Related Terms

Thank you for viewing the detailed overview of XBiotech's Interest Coverage provided by GuruFocus.com. Please click on the following links to see related term pages.


XBiotech (XBiotech) Business Description

Traded in Other Exchanges
Address
5217 Winnebago Lane, Austin, TX, USA, 78744
XBiotech Inc is a United States based clinical-stage biopharmaceutical company. It is engaged in discovering and developing True Human (antibody technology) monoclonal antibodies for treating a variety of diseases. The company focuses on developing Anti-IL-1 a therapeutic antibody as a treatment for cancer. Geographically, all of its operations are in the United States.
Executives
Angela Hu officer: Principle Financial Officer 5217 WINNEBAGO LN, AUSTIN TX 78744
John Simard director, 10 percent owner 8201 E RIVERSIDE DRIVE, BLDG 4, STE 100, AUSTIN TX 78744
Bay Street Financial S.a. 10 percent owner MEIERHOFSTRASSE 5, LIECHTENSTEIN N2 9490 VADUZ
W Thorpe Mckenzie director, 10 percent owner 735 BROAD ST, STE 1105, CHATTANOOGA TN 37402
Sushma Shivaswamy officer: VP of R&D 8201 E RIVERSIDE DRIVE, BLDG 4, STE 100, AUSTIN TX 78744
Queena Han officer: VP of Fin & HR, Secretary 8201 E RIVERSIDE DRIVE, BLDG 4 STE 100, AUSTIN TX 78744
Thomas Gut 10 percent owner CO LINDENBERG FAMILY OFFICE LTD, LATERNENGASSE 5, ZURICH V8 8001
Peter Libby director 109 LARCH ROAD, CAMBRIDGE MA 02138
Fondation Rennes 10 percent owner RATIKONSTRASSE 13, VADUZ, PRINCIPALITY OF LIECHTENSTEIN N2 FL-9490
Donald H. Macadam director 56 KELLY DRIVE, PORT DOVER A6 N0A 1N5
Jan-paul Waldin director 77 KING STREET WEST, SUITE 3000, TORONTO A6 M5K 1G8
Benjamin Guzman officer: Sr.VP Corp. Strategy & Finance 8201 E RIVERSIDE DR BLDG. 4 STE 100, AUSTIN TX 78744
Trey Benson officer: VP of Commercial Development 8201 E. RIVERSIDE DR., BUILDING 4, SUITE 100, AUSTIN TX 78744
Kalidip Choudhury officer: VP of Business Development 8201 E. RIVERSIDE DRIVE, BUILDING 4, SUITE 100, AUSTIN TX 78744
Dawn Mccollough officer: VP Clinical Operations 115 SANDRA MURAIDA WAY, #838, AUSTIN TX 78703